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Abstract
Background—Reducing racial/ethnic disparities in immunization rates is a compelling public 
health goal. Disparities in childhood vaccination rates have been absent in recent years for most 
vaccines.
Purpose—The objective of this study is to assess adult vaccination by race/ethnicity in the 
United States.
Methods—The 2012 National Health Interview Survey (NHIS) was analyzed in 2014 to assess 
adult vaccination by race/ethnicity for six vaccines routinely recommended for adults: The 
vaccines are: influenza, Tetanus, pneumococcal, human papilloma virus, and zoster vaccines. A 
multivariable logistic regression analysis was performed to identify factors independently 
associated with all adult vaccinations.
Results—Vaccination coverage was significantly lower among non-Hispanic blacks, Hispanics, 
and non-Hispanic Asians compared with non-Hispanic whites, with only a few exceptions. Age, 
sex, education, health insurance, usual place of care, number of physician visits in the past 12 
months, and health insurance were independently associated with receipt of most of the vaccines 
examined. Racial/ethnic differences narrowed, but gaps remained after taking these factors into 
account.
Conclusions—Racial and ethnic differences in vaccination levels narrow when adjusting for 
socioeconomic factors analyzed in this survey, but are not eliminated, suggesting that other factors 
that associated with vaccination disparities were not measured by the NHIS and could also 
contribute to the differences in coverage. Additional efforts including systems changes to ensure 
routine assessment and recommendations for needed vaccination among adults for all racial/ethnic 
groups are essential for improving vaccine coverage.
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Introduction
Every year thousands of adults in the United States suffer serious health problems, are 
hospitalized, and even die due to diseases for which vaccines are available.1 For example, an 
annual average of 226,000 people may be hospitalized due to influenza and 75% of the 
influenza hospitalizations are among patients aged ≥50 years.2 Annual deaths from influenza 
have ranged from approximately 3,000 to 49,000,3 with 90% of these deaths occurring 
among adults. Due to the widespread use of pneumococcal conjugate vaccine (PCV7) in 
children and the dramatic reductions of invasive pneumococcal disease (IPD) in children, by 
2012, approximately 32,000 cases of IPD occur, about 90% of which are among adults,1, 4 
and among those cases, as many as 3,300 die, with more than 95% of these deaths occurring 
among adults.1, 4 As many as 8,300 adults die annually from HPV-associated cancers.1 
About 1 million cases of shingles occur annually among older adults, with approximately 
10–50% suffering post-herpetic neuralgia. 5–7
Vaccination is the most effective strategy for preventing vaccine-preventable diseases and 
their complications. The adult immunization schedule,(8 updated annually by the Advisory 
Committee on Immunization Practices (ACIP), provides current recommendations for 
vaccinating adults and a ready resource for practitioners who provide health-care services 
for adults in various settings. Adult vaccination coverage, however, remains low for most 
routinely recommended vaccines and well below Healthy People 2020 targets. 9–11 Further, 
uptake of vaccines has historically been lower among all minority racial and ethnic groups 
compared to non-Hispanic white populations. 9, 12–25
Data from the 2012 National Health Interview Survey (NHIS) was used to assess national 
levels of vaccination by race and ethnicity in the United States for six vaccines (influenza, 
pneumococcal (including both polysaccharide and conjugate vaccines), tetanus (tetanus-
diphtheria toxoid [Td]), human papilloma virus (HPV), and herpes zoster (shingles)) 
routinely recommended for adults and to examine associations of vaccination uptake with 
demographic and access to care factors.
Methods
The 2012 NHIS were analyzed in 2014. The NHIS is an annual household survey conducted 
by the National Center for Health Statistics, Centers for Disease Control and Prevention, 
which collects health information on the U.S. civilian, non-institutionalized population.26 
The NHIS sample is selected through the use of complex sampling design involving 
stratification, clustering, and multistage sampling. Face to face interviews are conducted 
each week throughout the year in a probability sample of households. In the sample adult 
core, questions about receipt of recommended vaccinations for adults and other factors are 
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asked of one randomly selected adult within each family in the household. In 2012, the final 
response rate for the sample adult core was 61.2%.26
Vaccination coverage for influenza, pneumococcal, Td, shingles, and HPV vaccination from 
coded survey questions on receipt of these vaccines were assessed. To determine influenza 
vaccination status, respondents were asked “During the past 12 months, have you had a flu 
shot?” and “The seasonal flu vaccine sprayed in the nose is also called FluMist™. During the 
past 12 months, have you had a seasonal flu vaccine that was sprayed in your nose?” An 
affirmative answer to either question is considered receiving influenza vaccination. Racial/
ethnic groups were defined as non-Hispanic white only, non-Hispanic black only, non-
Hispanic Asian only, and other race. Other race includes American Indian/Alaska Native and 
persons reporting multiple races.
Selected adult vaccination coverage (influenza, pneumococcal, Td, shingles, HPV) was 
stratified by race and ethnicity. Persons with high-risk conditions for pneumococcal 
vaccination include those who reported asthma, diabetes, cardiovascular disease, liver 
disease, kidney disease, chronic obstructive pulmonary disease, emphysema, chronic 
bronchitis, cancer (excluding non-melanoma skin cancer), and current smoking.
SUDAAN statistical software (Research Triangle Institute, Research Triangle Park, NC) was 
used to calculate point estimates and 95% confidence intervals (CIs) of vaccination 
coverage.27 Data are weighted by age, sex, and race/ethnicity to reflect the adult civilian 
population of the United States. T tests were used to check for associations with the 
significance level set at α<0.05. Multivariable logistic and predictive marginal models were 
conducted to derive adjusted vaccination coverage, and to identify factors independently 
associated with vaccinations. Multivariable logistic regression and predictive marginal 
analyses on stratified samples by age were conducted to assess adjusted vaccination 
coverage and prevalence ratio adjusted for age group (19–64: 19–49, 50–64; 65+: 65–74, 
75–84, 85+; 60+: 60–64, 65–74,75–84, 85+; 19–26: 19–21, 22–26), sex (male/female), race/
ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, Asian, and other), marital 
status (married, widowed/divorced/separated, never married), education (less than high 
school, high school, some college or more), employment status (employed, unemployed, not 
in work force), number of physician contacts in the previous year (0, 1, 2–3, 4–9, 10 or 
more), routine place of care (yes, no), health insurance status (private, public, none), self-
reported health status (excellent/very good, good, fair, poor), duration of residence the 
United States (born in the U.S., born outside the U.S. and stayed < 10 years in the U.S., born 
outside the U.S. and stayed >=10 years in the U.S.), and region of residence (Northeast, 
Midwest, South, West). All variables listed were also included in multivariable models. 
Predictive marginal model is a multivariable analysis that could generate prevalence 
estimates adjusted for all variables in a multivariable logistic model using a direct 
standardization procedure. The NHIS was approved by Research Ethics Review Board (the 
ERB number is 2009–16) of the National Center for Health Statistics, Centers for Disease 
Control and Prevention.
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Results
A total of 34,218 adults ≥18 years from the 2012 NHIS were included in the study. The 
demographic characteristics of the study populations are shown in Table 1. For both age 
groups (19–64 and ≥65 years), the distribution of race and ethnicity differed significantly by 
all demographic and access to care characteristics (Table 1).
Influenza vaccination coverage among adults 19–64 years was 33.5% for non-Hispanic 
whites, 27.5% for non-Hispanic blacks, 25.3% for Hispanics, 37.4% for Asians, and 32.4% 
for other races (Table 2). Influenza vaccination coverage among adults ≥65 years was 68.8% 
for non-Hispanic whites, 53.0% for non-Hispanic blacks, 57.5% for Hispanics, 65.2% for 
Asians, and 56.5% for other races (Table 2). Pneumococcal vaccination coverage among 
adults 19–64 years with high-risk conditions was 21.4% for non-Hispanic whites, 19.7% for 
non-Hispanic blacks, 13.8% for Hispanics, 13.2% for Asians, and 20.2% for other races. 
Pneumococcal vaccination coverage among adults ≥65 years was 64.0% for non-Hispanic 
whites, 46.1% for non-Hispanic blacks, 43.4% for Hispanics, 41.3% for Asians, and 44.7% 
for other races. Tetanus vaccination coverage among adults 19–64 years was 68.9% for non-
Hispanic whites, 54.9% for non-Hispanic blacks, 53.6% for Hispanics, 52.8% for Asians, 
and 71.5% for other races. Tetanus vaccination coverage among adults ≥65 years was 57.7% 
for non-Hispanic whites, 44.6% for non-Hispanic blacks, 44.8% for Hispanics, 45.8% for 
Asians, and 50.2% for other races. Shingles vaccination coverage among adults ≥60 years 
was 22.8% for non-Hispanic whites, 8.8% for non-Hispanic blacks, 8.7% for Hispanics, 
16.9% for Asians, and 19.7% for other races. HPV vaccination coverage among female 
adults 19–26 years was 42.2% for non-Hispanic whites, 29.1% for non-Hispanic blacks, 
18.7% for Hispanics, 15.6% for Asians, and 41.2% for other races (Table 2).
Overall, vaccination coverage was significantly lower among non-Hispanic blacks compared 
with non-Hispanic whites, except for pneumococcal vaccination among persons 19–64 years 
with high-risk conditions (Table 2). Hispanics had significantly lower vaccination coverage 
compared with non-Hispanic whites for all the vaccines examined (Table 2). Except for 
influenza vaccination among persons 19–64 years, non-Hispanic Asians had significantly 
lower vaccination coverage compared with non-Hispanic whites for all the vaccines (Table 
2). Persons of other race had coverage similar to non-Hispanic whites except for 
pneumococcal vaccination among adults ≥ 65 years (Table 2). Vaccination coverage was 
similar among Hispanics compared with non-Hispanic blacks, except for pneumococcal 
vaccination among persons 19–64 years with high-risk conditions and HPV vaccination 
among females 19–26 years (Table 2). Other multiple comparisons are showed in Table 2.
For influenza and pneumococcal vaccination, smaller racial and ethnic disparities in the 19–
64 year age group were observed compared with adults ≥ 65 years of age (Table 2). 
Differences in vaccination compared with non-Hispanic whites among adults 19–64 years 
ranged from −1.1 (influenza vaccination among other racial/ethnic group) to −8.2 (influenza 
vaccination among Hispanics and pneumococcal vaccination among non-Hispanic Asians). 
Differences in vaccination compared with non-Hispanic whites among adults ≥65 years of 
age ranged from −3.6 (influenza vaccination among non-Hispanic Asians) to −22.7 
(pneumococcal vaccination among non-Hispanic Asians) (Table 2).
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In most of the multivariable logistic models, non-Hispanic blacks, Hispanics, and non-
Hispanic Asians were significantly less likely to receive vaccinations compared with non-
Hispanic whites after controlling for other demographic and access to care characteristics 
(including age, sex, marital status, education, employment status, health insurance, number 
of doctor visits in the past year, usual source of care, self-reported health status, duration of 
U.S. residence, and region of residence) (Table 3). Persons of other race had adjusted 
vaccination coverage similar to non-Hispanic whites except for pneumococcal vaccination 
among adults ≥65 years. Racial and ethnic differences in adjusted vaccination coverage 
narrowed compared with gaps in unadjusted vaccination coverage, but most of the coverage 
disparities remained statistically significant after taking these socio-demographic and access 
to care factors into account (Table 3). Other multiple comparisons are showed in Table 3.
Factors that were independently associated with each vaccination in the multivariable 
logistic models are shown in Table 4. Race and ethnicity, age, sex, education, health 
insurance, and usual place of care were independently associated with receipt of most of the 
vaccines examined (Table 4). The number of physician visits in the past 12 months was also 
independently associated with all the vaccinations assessed in this study. Having any health 
insurance was associated with adult vaccination coverage except for HPV vaccination 
among females (Table 4).
Discussion
Overall, vaccination coverage among non-Hispanic blacks, Hispanics, and non-Hispanic 
Asians was lower compared with that of non-Hispanic whites. Racial and ethnic differences 
narrowed, but gaps remained after taking into account socio-demographic and access to care 
factors for most vaccines and populations. Race and ethnicity, age, sex, education, health 
insurance, and having a usual place for medical care were independently associated with 
most of the vaccinations, and number of physician visits in the past 12 months was 
independently associated with all the vaccinations assessed in this study. For the three 
vaccines in this report that are included in Healthy People 2020 (influenza, pneumococcal, 
and herpes zoster) vaccination coverage in all race and ethnic groups was well below the 
respective target levels of 70% for influenza vaccination among adults ≥18 years, 60% for 
pneumococcal vaccination among adults 18–64 years with high-risk conditions, 90% for 
pneumococcal vaccination among adults ≥65 years, and 30% for shingles vaccination among 
adults ≥60 years.11
Although studies indicate that racial and ethnic disparities in childhood vaccination have 
been significantly reduced or not observed in recent data for some vaccinations,12, 13, 28 
racial and ethnic disparities in adult vaccination persist and have been reported previously.
9, 14–23
 School entry vaccination requirements and the Vaccines for Children program (VFC) 
which provides vaccines to uninsured children, children on Medicaid, and other selected 
children, might contribute to the reduced racial and ethnic disparities in vaccination 
coverage for children. 29–31 Multiple factors contribute to racial and ethnic differences in 
adult vaccination, including differences in attitudes toward vaccination and preventive care, 
propensity to seek and accept vaccination, variations in the likelihood that providers 
recommend vaccination, differences in quality of care received by racial and ethnic 
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populations, and differences in concerns about vaccination, including vaccine safety.9, 14–23 
Additionally, non-Hispanic black and Hispanic adults are more likely to be uninsured. In one 
study in 2011, uninsured prevalence was higher among non-Hispanic blacks (19.5%) and 
Hispanics (30.1%) compared with non-Hispanic whites (11.1%).32 Our study showed that 
health insurance had a positive impact on adult vaccination coverage. Lack of medical 
insurance has been an important predictor of low adult vaccination uptake.20–23, 33–34 The 
Affordable Care Act and other healthcare reform holds the promise of reducing the number 
of uninsured adults and related barriers to care and reducing missed opportunities for 
vaccination related to health insurance coverage and access to care.35, 36 Our data suggest, 
however, that health insurance, although beneficial in improving access to health care 
services, might not be sufficient in itself to achieve optimal adult vaccination. Additional 
effort will be needed to increase rates and close gaps in adult vaccination coverage.
Previous research has indicated a variety of possible causes for the continued racial and 
ethnic disparities in adult influenza and pneumococcal vaccination rates, including patient, 
provider, and system factors.14, 15, 17, 19 African-American older adults report more negative 
attitudes toward influenza vaccination than white adults;15, 24 however, studies of 
standardized offering of influenza and pneumococcal vaccines have demonstrated reductions 
in racial and ethnic coverage disparities.25, 37 Standardized offering of vaccination by 
healthcare provider to all eligible patients may work in part by addressing the fact that older 
African-American adults are less likely than whites to actively seek influenza vaccination.
38–39
 In another study, vaccination disparities were reduced among older adults using an 
intensive combination of patient tracking, vaccination reminders for providers and patients, 
and patient outreach and assistance. 40 Incorporating the standards of practice for adult 
immunizations, which include routinely assessing vaccination needs during clinical 
encounters, providing a strong recommendation for vaccination to patients in need of 
vaccines, and then offering vaccination at the visit, can have a significant impact on 
coverage and reduce disparities.41
Shingles and HPV vaccination have been recommended for adults since 2006–2007. 42–43 
Gaps in early uptake of these vaccines by race and ethnicity after 1–2 years following ACIP 
recommendations were small and not statistically significant.33, 34, 44 Racial and ethnic gaps 
in vaccination might not be apparent during the first few years following ACIP 
recommendations. Our study showed that, in 2012, shingles and HPV vaccination coverage 
were generally significantly lower among non-Hispanic blacks and Hispanics compared with 
non-Hispanic whites. One of the reasons that might contribute to lower coverage is 
differential awareness of those three newer vaccines. Studies have shown that awareness of 
shingles, and HPV vaccines was significantly lower among racial and ethnic minorities 
compared with non-Hispanic whites.33, 34, 44
Studies have shown that healthcare provider recommendations for vaccination are strongly 
associated with vaccination coverage.20–23, 44–47 In this report, number of physician visits in 
the past 12 months was independently associated with all adult vaccinations assessed in this 
study. This finding was consistent with previous studies20–23 and suggests that physician 
contact might have facilitated a discussion about vaccines that were indicated and a 
recommendation and decision to vaccinate.
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The findings in this report are subject to limitations. First, adult vaccination coverage was 
self-reported and therefore might be subject to recall bias. However, self-reported influenza 
(previous 12 months), pneumococcal polysaccharide (ever received), hepatitis A (ever 
received), hepatitis B (ever received), shingles (received since 2006) and HPV vaccination 
status (received since 2005) among adults have been shown to be sensitive and specific.48–52 
In one study, self-reported tetanus vaccination (received last 10 years) was sensitive but not 
specific.52 Additional study is needed for accuracy of recall by young adults of vaccinations 
they may have been received as children or adolescents (HPV, Tdap, HepB). The findings 
for HPV vaccination among younger females 18–26 years should be viewed with caution, 
based on comparison with estimates based on provider-reported vaccinations from the NIS-
Teen.53 While from NHIS we observed a large disparity with lower coverage among 
Hispanics, NIS-Teen estimates indicate that among girls age 17 years in 2008–2010 (ages 
19–21 in 2012), Hispanic girls had higher HPV vaccination initiation coverage than non-
Hispanic white girls. Second, other factors associated with vaccination disparities were not 
measured by the NHIS and could not be ascertained in this analysis. Finally, it might be 
more difficult to identify disparities with low vaccination rates (e.g., shingles vaccination 
rate was <30%).
Adult vaccination coverage remains suboptimal, particularly among racial and ethnic 
minority groups. Substantial improvement in vaccination of recommended groups is needed 
to maximally reduce the health impact of vaccine-preventable diseases. To improve coverage 
and eliminate disparities in adult vaccination, greater implementation of evidence-based 
interventions are needed, including the use of reminder/recall systems, standing orders for 
vaccination, regular assessments of vaccination coverage levels among provider practices, 
vaccination registries, and improving public and provider awareness of the importance of 
vaccinations for adults.9, 21–23, 25, 37, 41, 54–55 Broad use of interventions to remove barriers 
to access and to make offering of adult vaccines in health care and other settings a routine 
practice are important components of efforts to reduce adult vaccination disparities (e.g., 
influenza vaccine has been available in multiple settings for many years, and gaps in 
vaccination coverage among non-Hispanic blacks and Asians were slightly reduced 
compared to non-Hispanic white from 2007 to 2012).21, 23, 55 Multi-sector collaborations 
including culturally relevant communications to reach specific target populations and 
implementation of effective interventions are important for reducing vaccination and other 
health disparities in the United States.56, 57 Routine monitoring and reporting of vaccine 
coverage by race and ethnicity and other socio-demographic factors might also help reduce 
racial and ethnic disparities.58 Identifying other factors associated with vaccination that are 
not currently measured by health surveys like the NHIS is also needed.
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